Table 2.
Patient clinical characteristics at baseline (full analysis set).
| Characteristic | Full analysis set (N = 737) |
|---|---|
| Time since MDD diagnosis (years), mean ± SD | 11.2 ± 12.1 |
| Median (range) | 7.0 (0–58) |
| Duration of current MDE (weeks), mean ± SD | 47.0 ± 140.8 |
| ≤ 14 weeks, n (%) | 409 (55.6) |
| >14 weeks, n % | 326 (44.4) |
| No. of previous MDEs, mean ± SD | 4.4 ± 9.1 |
| 0 previous MDEs, n (%) | 151 (20.5) |
| 1 previous MDE, n (%) | 157 (21.4) |
| 2+ previous MDEs, n (%) | 427 (58.1) |
| Vortioxetine treatment line for current MDE, n (%) | |
| 1st line | 321 (43.6) |
| 2nd line | 257 (34.9) |
| ≥3rd line | 159 (21.6) |
| Vortioxetine dose (mg/day), mean ± SD | |
| Baseline | 9.6 ± 5.5 |
| Week 24 | 12.9 ± 6.5 |
| Clinical assessment scores, mean ± SD | |
| SDS total score | 19.6 ± 6.6 |
| Work/school domain | 6.3 ± 2.7 |
| Family life/home responsibilities domain | 6.6 ± 2.4 |
| Social life/leisure activities domain | 6.7 ± 2.4 |
| PHQ-9 | 16.5 ± 5.5 |
| PDQ-D-5 | 11.2 ± 4.9 |
| DSST | 42.6 ± 16.8 |
| EQ-5D-5L utility score | 0.65 ± 0.16 |
| ASEX | 22.1 ± 6.5 |
| CGI-S | 4.3 ± 0.9 |
| Work productivity measures, mean ± SD | |
| Absenteeism (days/week) | 2.2 ± 2.7 |
| Presenteeism (days/week) | 4.0 ± 2.6 |
| Sick leave (days in the past 12 weeks) | 26.6 ± 29.1 |
Absenteeism, SDS days lost for working population; ASEX, Arizona Sexual Experience Scale (score range 5–30); CGI-S, Clinical Global Impression–Severity (score range 1–7); DSST, Digit Symbol Substitution Test (score range 0–133); EQ-5D-5L, EuroQoL 5 dimensions 5 levels utility index (score range 0–1); MDD, major depressive disorder; MDE, major depressive episode; PDQ-D-5, 5-item Perceived Deficits Questionnaire-Depression (score range 0–20); PHQ-9, 9-item Patient Health Questionnaire (score range, 0–27); Presenteeism, SDS days underproductive for working population; SD, standard deviation; SDS, Sheehan Disability Scale.